SAN DIEGO, Calif.--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates two years of progress in pioneering a novel non-profit approach to providing personalized experimental antisense ...
n-Lorem’s Patient Empowerment Program Approaches One Year Mark With More Than 5000 Episode Downloads
SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates a year of connecting with the nano-rare community through its patient advocacy initiative referred to as the ‘Patient ...
n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for patients living with genetic diseases, today ...
SAN DIEGO, April 21, 2026--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, announced today that the 50 th nano-rare patient has been treated with a personalized, experimental antisense ...
SAN DIEGO and GENEVA, Jan. 12, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...
Foundation’s collaboration with premier rare disease company strengthens efforts to reach more patients in need n-Lorem Foundation is the first and only foundation with a mission to provide ...
Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis ...
The MarketWatch News Department was not involved in the creation of this content. n-Lorem Foundation Has Treated 15 Nano-rare Patients and Expects to Treat More Than 25 Nano-rare Patients by Year End ...
No ASO-related serious adverse events and an excellent overall safety and tolerability record One patient treated for more than three years and 24 patients treated for >1 year n-Lorem, a nonprofit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results